HER2 expression should be routinely evaluated in DCIS to avoid under or overtreatment!
作者信息
Garg Nidhi, Thorat Mangesh A
出版信息
Oncoscience. 2023 Jan 30;10:1-3. doi: 10.18632/oncoscience.572. eCollection 2023.
Abstract
摘要
相似文献
1
HER2 expression should be routinely evaluated in DCIS to avoid under or overtreatment!应在导管原位癌中常规评估HER2表达，以避免治疗不足或过度治疗！
Oncoscience. 2023 Jan 30;10:1-3. doi: 10.18632/oncoscience.572. eCollection 2023.
2
The prognostic role of HER2 expression in ductal breast carcinoma in situ (DCIS); a population-based cohort study.人表皮生长因子受体2（HER2）表达在导管原位癌（DCIS）中的预后作用：一项基于人群的队列研究。
BMC Cancer. 2015 Jun 11;15:468. doi: 10.1186/s12885-015-1479-3.
3
Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast.HER4表达缺失可预测乳腺导管原位癌的复发。
Clin Cancer Res. 2005 Mar 15;11(6):2163-8. doi: 10.1158/1078-0432.CCR-04-1633.
4
The clinical significance of HER2 expression in DCIS.HER2表达在导管原位癌中的临床意义。
Med Oncol. 2022 Nov 9;40(1):16. doi: 10.1007/s12032-022-01876-9.
5
Tumour-infiltrating lymphocytes add prognostic information for patients with low-risk DCIS: findings from the SweDCIS randomised radiotherapy trial.肿瘤浸润淋巴细胞为低风险导管原位癌患者增加预后信息：来自瑞典导管原位癌随机放疗试验的结果
Eur J Cancer. 2022 Jun;168:128-137. doi: 10.1016/j.ejca.2022.01.016. Epub 2022 Feb 27.
6
Evaluating the Risk of Upstaging HER2-Positive DCIS to Invasive Breast Cancer.评估 HER2 阳性 DCIS 升级为浸润性乳腺癌的风险。
Ann Surg Oncol. 2017 Oct;24(10):2999-3003. doi: 10.1245/s10434-017-5941-0. Epub 2017 Aug 1.
7
Biological Markers Predictive of Invasive Recurrence in DCIS.预测导管原位癌侵袭性复发的生物标志物
Clin Med Oncol. 2008;2:7-18. Epub 2008 Jan 22.
8
Triple-negative and HER2 positive ductal carcinoma in situ of the breast: characteristics, behavior, and biomarker profile.乳腺三阴性和 HER2 阳性导管原位癌：特征、行为和生物标志物特征。
Virchows Arch. 2018 Sep;473(3):275-283. doi: 10.1007/s00428-018-2416-z. Epub 2018 Jul 23.
9
Comparison of HER2 amplification status among breast cancer subgroups offers new insights in pathways of breast cancer progression.乳腺癌亚组间HER2扩增状态的比较为乳腺癌进展途径提供了新见解。
Virchows Arch. 2017 Nov;471(5):575-587. doi: 10.1007/s00428-017-2161-8. Epub 2017 May 31.
10
The clinical and biological significance of HER2 over-expression in breast ductal carcinoma in situ: a large study from a single institution.HER2 过表达在乳腺导管原位癌中的临床和生物学意义：来自单一机构的大型研究。
Br J Cancer. 2019 May;120(11):1075-1082. doi: 10.1038/s41416-019-0436-3. Epub 2019 May 8.
引用本文的文献
1
SITC strategic vision: prevention, premalignant immunity, host and environmental factors.肿瘤免疫治疗学会战略愿景：预防、癌前免疫、宿主及环境因素。
J Immunother Cancer. 2025 Mar 28;13(3):e010419. doi: 10.1136/jitc-2024-010419.
2
Systematic assessment of HER2 status in ductal carcinoma in situ of the breast: a perspective on the potential clinical relevance.系统评估乳腺导管原位癌的 HER2 状态：潜在临床相关性的视角。
Breast Cancer Res. 2024 Aug 27;26(1):125. doi: 10.1186/s13058-024-01875-w.
3
Tools to Guide Radiation Oncologists in the Management of DCIS.指导放射肿瘤学家管理导管原位癌的工具。
Healthcare (Basel). 2024 Apr 6;12(7):795. doi: 10.3390/healthcare12070795.
本文引用的文献
1
Prognostic Risk Assessment and Prediction of Radiotherapy Benefit for Women with Ductal Carcinoma In Situ (DCIS) of the Breast, in a Randomized Clinical Trial (SweDCIS).在一项随机临床试验（SweDCIS）中，对乳腺导管原位癌（DCIS）女性患者的放疗获益进行预后风险评估和预测
Cancers (Basel). 2021 Dec 3;13(23):6103. doi: 10.3390/cancers13236103.
2
Randomized Phase III Trial Evaluating Radiation Following Surgical Excision for Good-Risk Ductal Carcinoma In Situ: Long-Term Report From NRG Oncology/RTOG 9804.随机 III 期临床试验评估手术切除后低危导管原位癌的放疗：NRG 肿瘤学/RTOG9804 的长期报告。
J Clin Oncol. 2021 Nov 10;39(32):3574-3582. doi: 10.1200/JCO.21.01083. Epub 2021 Aug 18.
3
Prognostic and Predictive Value of HER2 Expression in Ductal Carcinoma In Situ: Results from the UK/ANZ DCIS Randomized Trial.HER2 表达在导管原位癌中的预后和预测价值：来自英国/澳新 DCIS 随机试验的结果。
Clin Cancer Res. 2021 Oct 1;27(19):5317-5324. doi: 10.1158/1078-0432.CCR-21-1239.
4
Prognostic Value of ER and PgR Expression and the Impact of Multi-clonal Expression for Recurrence in Ductal Carcinoma : Results from the UK/ANZ DCIS Trial.ER 和 PgR 表达的预后价值及多克隆表达对导管癌复发的影响：来自英国/澳新 DCIS 试验的结果。
Clin Cancer Res. 2021 May 15;27(10):2861-2867. doi: 10.1158/1078-0432.CCR-20-4635. Epub 2021 Mar 16.
5
Clinicopathological Risk Factors for an Invasive Breast Cancer Recurrence after Ductal Carcinoma -A Nested Case-Control Study.导管癌浸润性乳腺癌复发的临床病理危险因素-巢式病例对照研究。
Clin Cancer Res. 2018 Aug 1;24(15):3593-3601. doi: 10.1158/1078-0432.CCR-18-0201. Epub 2018 Apr 23.
6
Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.阿那曲唑与他莫昔芬用于接受肿块切除术加放疗的绝经后原位导管癌女性患者的疗效比较（NSABP B-35）：一项随机、双盲、3期临床试验。
Lancet. 2016 Feb 27;387(10021):849-56. doi: 10.1016/S0140-6736(15)01168-X. Epub 2015 Dec 11.
7
Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial.阿那曲唑与他莫昔芬预防局部切除原位导管癌的绝经后妇女局部及对侧乳腺癌（IBIS-II DCIS）：一项双盲、随机对照试验
Lancet. 2016 Feb 27;387(10021):866-73. doi: 10.1016/S0140-6736(15)01129-0. Epub 2015 Dec 11.
8
The prognostic role of HER2 expression in ductal breast carcinoma in situ (DCIS); a population-based cohort study.人表皮生长因子受体2（HER2）表达在导管原位癌（DCIS）中的预后作用：一项基于人群的队列研究。
BMC Cancer. 2015 Jun 11;15:468. doi: 10.1186/s12885-015-1479-3.
9
Breast-conserving treatment with or without radiotherapy in ductal carcinoma In Situ: 15-year recurrence rates and outcome after a recurrence, from the EORTC 10853 randomized phase III trial.保乳治疗联合或不联合放疗治疗导管原位癌：来自 EORTC 10853 随机 III 期试验的 15 年复发率和复发后的结果。
J Clin Oncol. 2013 Nov 10;31(32):4054-9. doi: 10.1200/JCO.2013.49.5077. Epub 2013 Sep 16.
10
Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS.保乳术后 NSABP B-17 和 B-24 随机临床试验中同侧乳腺肿瘤局部复发的长期结果：DCIS 患者的报告。
J Natl Cancer Inst. 2011 Mar 16;103(6):478-88. doi: 10.1093/jnci/djr027. Epub 2011 Mar 11.
Zotero 插件